The Alzheimer’s Drug Discovery Foundation (ADDF) has just awarded a $2.1 million grant to R. Scott Turner, MD, PhD, of Georgetown University Medical Center. The grant is to conduct a phase II clinical trial of low-dose nilotinib, an FDA-approved drug for the treatment of adult chronic myeloid leukemia, in patients with Alzheimer’s disease. Nilotinib is … Continue reading “Could This Cancer Drug Help Alzheimer’s Patients?”
